- Home
- ANNX vs PCN Comparison
ANNX vs PCN Comparison
Compare ANNX & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- PCN
- Stock Information
- Founded
- ANNX 2011
- PCN 2001
- Country
- ANNX United States
- PCN United States
- Employees
- ANNX N/A
- PCN N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- PCN Investment Managers
- Sector
- ANNX Health Care
- PCN Finance
- Exchange
- ANNX Nasdaq
- PCN Nasdaq
- Market Cap
- ANNX 668.8M
- PCN 728.5M
- IPO Year
- ANNX 2020
- PCN N/A
- Fundamental
- Price
- ANNX $5.14
- PCN $13.99
- Analyst Decision
- ANNX Strong Buy
- PCN
- Analyst Count
- ANNX 7
- PCN 0
- Target Price
- ANNX $15.80
- PCN N/A
- AVG Volume (30 Days)
- ANNX 1.4M
- PCN 218.7K
- Earning Date
- ANNX 11-14-2024
- PCN 01-01-0001
- Dividend Yield
- ANNX N/A
- PCN 9.73%
- EPS Growth
- ANNX N/A
- PCN N/A
- EPS
- ANNX N/A
- PCN N/A
- Revenue
- ANNX N/A
- PCN N/A
- Revenue This Year
- ANNX N/A
- PCN N/A
- Revenue Next Year
- ANNX N/A
- PCN N/A
- P/E Ratio
- ANNX N/A
- PCN N/A
- Revenue Growth
- ANNX N/A
- PCN N/A
- 52 Week Low
- ANNX $2.27
- PCN $10.70
- 52 Week High
- ANNX $8.40
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- ANNX 20.42
- PCN 56.65
- Support Level
- ANNX $5.05
- PCN $13.91
- Resistance Level
- ANNX $7.63
- PCN $14.00
- Average True Range (ATR)
- ANNX 0.37
- PCN 0.10
- MACD
- ANNX -0.23
- PCN 0.01
- Stochastic Oscillator
- ANNX 3.68
- PCN 69.35
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income. The secondary investment objective of the fund is capital preservation and appreciation. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.